ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute
Rhea-AI Summary
ScaleReady has awarded a G-Rex Grant of $200,000 to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute. The grant will support process development and IND enabling studies for a novel KRAS-targeted TCR-T cell therapy.
Dr. Tran plans to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors. The project will utilize Bio-Techne's new GMP cytokines, designed for one-touch G-Rex close process manufacturing.
The G-Rex Grant Program is a $20M initiative by ScaleReady to advance cell and gene-modified cell therapy development and manufacturing. Recipients gain access to support from G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality and regulatory affairs, and CGT business operations.
Positive
- ScaleReady awarded a $200,000 G-Rex Grant to support development of a novel KRAS-targeted TCR-T cell therapy
- The grant will help expedite an IND application for a Phase 1/1b clinical trial
- Implementation of fully-closed system G-Rex bioreactors and Bio-Techne's GMP cytokines to optimize manufacturing process
Negative
- None.
News Market Reaction – TECH
In the trading session that priced this news, TECH gained 0.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"We have utilized G-Rex devices for a long time for our adoptive cell therapy efforts. This G-Rex Grant will substantially defray the costs associated with bringing our next generation TCR-T cell therapy into the clinic and advance the state of our manufacturing," said Dr. Tran
"Dr. Tran has been contributing to the field of cell and gene therapy for nearly 15 years and we are grateful for the opportunity to award a G-Rex Grant to Dr. Tran and the Providence Cancer Institute.
As part of the G-Rex Grant, Dr. Tran plans to optimize their manufacturing process by reducing the process duration and implementing fully-closed system G-Rex bioreactors. Dr. Tran will make use of Bio-Techne's new GMP cytokines that have been right-sized for one-touch G-Rex close process manufacturing, setting the stage for simple and efficient scale out.
ScaleReady's G-Rex® Grant Program is a
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
About Providence Cancer Institute of
Providence Cancer Institute of
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute-302269620.html
SOURCE Bio-Techne Corporation